Newsfeeds - Spark Newswire

21 minute read

Earnings Scheduled For August 3, 2021

Today, 11:32 PM

Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.

AAIC

9 minute read

Stocks That Hit 52-Week Highs On Monday

By Benzinga Insights

Today, 11:32 PM

This morning 121 companies reached new 52-week highs.

AAP

6 minute read

The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs

By Shanthi Rexaline

Today, 11:32 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22)

ACOR

8 minute read

Alzheimer’s Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What’s Next?

By TD Ameritrade

Today, 11:32 PM

For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.

ACAD

3 minute read

The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs

By Shanthi Rexaline

Today, 11:32 PM

Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks. There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.

ABT

1 minute read

AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA

By Vandana Singh

Today, 11:32 PM

AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market.

ABBV

2 minute read

Understanding Eli Lilly’s Unusual Options Activity

By Benzinga Insights

Today, 11:32 PM

On Friday, shares of Eli Lilly (NYSE:LLY) saw unusual options activity. After the option alert, the stock price moved up to $231.91.

LLY

2 minute read

FDA
News

Eli Lilly And Co, Incyte Say FDA Will Not Meet Prescription Drug User Fee Act Action Date For Supplemental New Drug Application For Baricitinib For Treatment Of Adults With Moderate To Severe Atopic Dermatitis

By Benzinga Newsdesk

Today, 11:32 PM

Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new

INCY

2 minute read

Unusual Options Activity Insight: Eli Lilly

By Benzinga Insights

Today, 11:32 PM

Shares of Eli Lilly (NYSE:LLY) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $232.81.

LLY

2 minute read

Eli Lilly And Co, Banner Alzheimer’s Institute Collaborate On Planned Phase 3 Prevention Trial Of Donanemab; Terms Not Disclosed

By Benzinga Newsdesk

Today, 11:32 PM

Eli Lilly and Company (NYSE:LLY) and Banner Alzheimer's Institute today announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study evaluating donanemab

LLY